TABLE 1.
Baseline characteristics.
| All | Cw-DSA | DP-DSA | |||
|---|---|---|---|---|---|
| n = 183 | n = 92 | n = 91 | p-value | n | |
| Transplant centers | 0.633 | 183 | |||
| Amiens | 8 (4.37%) | 5 (5.43%) | 3 (3.30%) | ||
| Bordeaux | 57 (31.1%) | 28 (30.4%) | 29 (31.9%) | ||
| Lille | 72 (39.3%) | 33 (35.9%) | 39 (42.9%) | ||
| Nantes | 46 (25.1%) | 26 (28.3%) | 20 (22.0%) | ||
| Recipients | |||||
| Age (years) | 51.5 (±13.0) | 51.7 (±13.4) | 51.2 (±12.7) | 0.809 | 183 |
| Sex (% of men) | 86 (46.9%) | 46 (50.0%) | 40 (43.9%) | 0.502 | 183 |
| BMI (kg/m2) | 24.7 (±4.85) | 25.4 (±5.22) | 23.9 (±4.34) | 0.049 | 178 |
| Rank of transplantation | 0.090 | 183 | |||
| 1 | 89 (48.6%) | 52 (56.5%) | 37 (40.7%) | ||
| 2 | 73 (39.9%) | 30 (32.6%) | 43 (47.3%) | ||
| 3 | 20 (10.9%) | 10 (10.9%) | 10 (11.0%) | ||
| 5 | 1 (0.55%) | 0 (0.00%) | 1 (1.10%) | ||
| ABO blood group | 0.488 | 183 | |||
| A | 84 (45.9%) | 47 (51.1%) | 37 (40.7%) | ||
| B | 18 (9.84%) | 8 (8.70%) | 10 (11.0%) | ||
| AB | 5 (2.73%) | 3 (3.26%) | 2 (2.20%) | ||
| O | 76 (41.5%) | 34 (37.0%) | 42 (46.2%) | ||
| Time spent in waiting list (days) | 1,128 (±1,320) | 1,294 (±1,692) | 961 (±758) | 0.088 | 183 |
| RRT technique | 0.662 | 183 | |||
| Preemptive transplant | 18 (9.84%) | 9 (9.78%) | 9 (9.89%) | ||
| Hemodialysis | 156 (85.2%) | 80 (87.0%) | 76 (83.5%) | ||
| Peritoneal dialysis | 9 (4.92%) | 3 (3.26%) | 6 (6.59%) | ||
| Initial nephropathy | 0.697 | 183 | |||
| Undetermined | 21 (11.5%) | 11 (12.0%) | 10 (11.0%) | ||
| Glomerular | 79 (43.2%) | 39 (42.4%) | 40 (44.0%) | ||
| Vascular | 18 (9.84%) | 7 (7.61%) | 11 (12.1%) | ||
| Tubulo-interstitial | 11 (6.01%) | 4 (4.35%) | 7 (7.69%) | ||
| Polycystic | 27 (14.8%) | 16 (17.4%) | 11 (12.1%) | ||
| Uropathy | 27 (14.8%) | 15 (16.3%) | 12 (13.2%) | ||
| Other organ transplant | 0.617 | 181 | |||
| Pancreas | 4 (2.21%) | 1 (1.09%) | 3 (3.37%) | ||
| Liver | 2 (1.10%) | 1 (1.09%) | 1 (1.12%) | ||
| Lung | 1 (0.55%) | 0 (0.00%) | 1 (1.12%) | ||
| cPRA (%) | 69.3 (±35.1) | 61.5 (±37.3) | 77.3 (±31.0) | 0.002 | 183 |
| Anti-HLA classe I | 159 (89.3%) | 92 (100%) | 67 (77.9%) | <0.001 | 178 |
| Anti-HLA classe II | 135 (76.3%) | 46 (53.5%) | 91 (100%) | <0.001 | 177 |
| Donors | |||||
| Age (years) | 53.3 (±16.5) | 53.2 (±16.4) | 53.5 (±16.7) | 0.928 | 183 |
| Sex (% of men) | 99 (54.1%) | 53 (57.7%) | 46 (50.5%) | 0.418 | 183 |
| BMI (kg/m2) | 26.9 (±5.66) | 27.4 (±6.06) | 26.3 (±5.18) | 0.176 | 183 |
| Donor type | 0.090 | 183 | |||
| Vascular brainstem death | 95 (51.9%) | 53 (57.6%) | 42 (46.2%) | ||
| Non-vascular brainstem death | 78 (42.6%) | 32 (34.8%) | 46 (50.5%) | ||
| Living donor | 6 (3.28%) | 5 (5.43%) | 1 (1.10%) | ||
| Maastricht III | 4 (2.19%) | 2 (2.17%) | 2 (2.20%) | ||
| ABO blood group | 0.174 | 183 | |||
| A | 68 (37.2%) | 38 (41.3%) | 30 (33.0%) | ||
| B | 12 (6.56%) | 8 (8.70%) | 4 (4.40%) | ||
| AB | 4 (2.19%) | 3 (3.26%) | 1 (1.10%) | ||
| O | 76 (41.5%) | 34 (37.0%) | 42 (46.2%) | ||
| Cold ischemia time (min) | 1,074 (±490) | 1,015 (±536) | 1,133 (±435) | 0.106 | 181 |
| Perfusion machine use | 58 (31.7%) | 32 (34.8%) | 26 (28.6%) | 0.457 | 183 |
BMI, body mass index; cPRA, calculated panel-reactive antibody; RRT, renal replacement therapy.